The taxane-based therapy provides survival benefit in patients with
metastatic prostate cancer; however, the average survival is less than 20
months due to the partial taxane-related chemoresistance. Innovative
strategies are needed to overcome the chemoresistance for improved patient
survival. In this project, paclitaxel-resistance was developed on
androgen-independent PC3 and androgen-dependent 22Rv1 and LNCaP human
prostate cancer (PCa) cell lines to investigate the efficacy of methyl
jasmonate (MeJa), an anti-cancer drug, in overcoming the chemoresistance.
The PCa cell lines were maintained in RPMI-1640 medium supplemented with 10%
fetal bovine serum (FBS) at 37?C under 5% CO2. The cell lines were exposed
to the gradually increasing doses of paclitaxel. Since the resistance on
LNCaP could not be achieved, the study was continued with 22Rv1 cell line.
It was demonstrated that paclitaxel-resistant cell lines overexpress ABCB1.
Resistance levels of cells and MeJa activity in all resistant and parental
lines were measured using CellTiter-Glo? luminescent assay. Test results
were compared with Student?s t-test or analysis of variance (ANOVA). P?0.05
(two-tailed) was considered to be significant. In conclusion, MeJa showed
more cytotoxicity on paclitaxel resistant PC3 (PC3-PtxR) cells than
resistant 22Rv1 (22Rv1-PtxR) cells. Detection of cytotoxic effects of MeJa
in overcoming paclitaxel resistance may contribute to the development of
alternative new compounds for the prevention or chemosensitization of
resistance to chemotherapeutics such as paclitaxel.
The establishment of two paclitaxel-resistant prostate cancer cell lines and the mechanisms of paclitaxel resistance with two cell lines
